CYCN offering history
Every offering-related filing in Cyclerion Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 359 filings back to Oct 9, 2018.
| Date | Filing | What it means | |
|---|---|---|---|
| Jul 24, 2026 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Jul 24, 2026 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| May 15, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| May 7, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 6, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Mar 25, 2025 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Feb 12, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Feb 4, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| May 25, 2023 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| May 12, 2023 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Jun 24, 2021 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Jun 23, 2021 | S-3/A → | REGISTERED | S-3/A registration — capacity to sell shares, not a sale yet |
| Jun 23, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jun 16, 2021 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jun 4, 2021 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Sep 3, 2020 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Aug 17, 2020 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Aug 14, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Aug 7, 2020 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jul 31, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jul 30, 2020 | S-3/A → | REGISTERED | S-3/A registration — capacity to sell shares, not a sale yet |
| Jul 24, 2020 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Apr 23, 2019 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Apr 23, 2019 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Apr 18, 2019 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
| Apr 2, 2019 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
CYCN offering FAQ
When did CYCN last execute an offering?
Per SEC filings, Cyclerion Therapeutics, Inc.'s most recent priced offering document is a 424B5 filed 2025-05-07. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did CYCN last announce or register an offering?
The most recent registration is a S-3 filed 2025-05-06. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.